UA113080C2 - A SPECIFIC ANTIBODY THAT SPECIFICALLY Binds to IL17 AND BAFF - Google Patents

A SPECIFIC ANTIBODY THAT SPECIFICALLY Binds to IL17 AND BAFF

Info

Publication number
UA113080C2
UA113080C2 UAA201411015A UAA201411015A UA113080C2 UA 113080 C2 UA113080 C2 UA 113080C2 UA A201411015 A UAA201411015 A UA A201411015A UA A201411015 A UAA201411015 A UA A201411015A UA 113080 C2 UA113080 C2 UA 113080C2
Authority
UA
Ukraine
Prior art keywords
antibody
baff
specifically binds
specific antibody
relates
Prior art date
Application number
UAA201411015A
Other languages
Ukrainian (uk)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/036677 external-priority patent/WO2013158577A1/en
Publication of UA113080C2 publication Critical patent/UA113080C2/en

Links

Landscapes

  • Peptides Or Proteins (AREA)

Abstract

Винахід стосується біспецифічного антитіла, яке специфічно зв'язується з фактором активування В-клітин родини TNF (BAFF) та інтерлейкіном-17А (IL-17). Винахід також стосується молекули ДНК, що містить нуклеотидну послідовність, що кодує заявлене антитіло, клітини-ссавця, що містить ДНК, способу продукування антитіла, фармацевтичної композиції, що містить антитіло, та способу лікування вовчакового нефриту (LN), системного червоного вовчака (SLE), ревматоїдного артриту (RA), псоріазу (Ps), анкілозивного спондилоартриту (AS), псоріатичного артриту (РА), первинного синдрому Шегрена (pSS) або множинної мієломи (MM) за допомогою вказаного біоспецифічного антитіла.The invention relates to a bispecific antibody that specifically binds to TNF (BAFF) and IL-17A (IL-17) activation factor. The invention also relates to a DNA molecule containing the nucleotide sequence encoding the claimed antibody, mammalian cells containing DNA, a method of producing the antibody, a pharmaceutical composition containing the antibody, and a method of treatment of lupus nephritis (LN), systemic lupus erythematosus (SLE) , rheumatoid arthritis (RA), psoriasis (Ps), ankylosing spondylitis (AS), psoriatic arthritis (RA), primary Sjogren's syndrome (pSS) or multiple myeloma (MM) using the specified biospecific antibody.

UAA201411015A 2012-04-20 2013-04-16 A SPECIFIC ANTIBODY THAT SPECIFICALLY Binds to IL17 AND BAFF UA113080C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261636302P 2012-04-20 2012-04-20
PCT/US2013/036677 WO2013158577A1 (en) 2012-04-20 2013-04-16 Anti-baff-anti-il-17 bispecific antibodies

Publications (1)

Publication Number Publication Date
UA113080C2 true UA113080C2 (en) 2016-12-12

Family

ID=58044249

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201411015A UA113080C2 (en) 2012-04-20 2013-04-16 A SPECIFIC ANTIBODY THAT SPECIFICALLY Binds to IL17 AND BAFF

Country Status (2)

Country Link
MA (1) MA37425B1 (en)
UA (1) UA113080C2 (en)

Also Published As

Publication number Publication date
MA37425A1 (en) 2017-10-31
MA37425B1 (en) 2018-12-31

Similar Documents

Publication Publication Date Title
EA201491622A1 (en) BISPECIFIC ANTIBODIES AGAINST BAFF AND IL-17
BR112015018203A2 (en) ANTI-TNF-ANTI-IL-17 BISPECIFIC ANTIBODIES
UA117575C2 (en) ANTIBODY WHICH SPECIFICALLY Binds to IL-17A AND ITS APPLICATION
ECSP17047155A (en) PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF ANTIBODIES AGAINST IL-17
TR201909531T4 (en) ANTI-IL-17 ANTIBODIES USING ANKILOSANE SPONDILITE TREATMENT METHODS
CY1122399T1 (en) COMPETITIVE TNF RECEPTOR BINDING FACTORS
HRP20200174T1 (en) Anti-blood dendritic cell antigen 2 antibodies and uses thereof
UA116766C2 (en) A Binding molecule that is biospecific to CCMA and CD3
UA116614C2 (en) FACTOR ANTIBODY AND ITS APPLICATION
MX2019011656A (en) Improved antigen binding receptor formats.
EA201492101A1 (en) ANTIBODIES AGAINST FCRN
EP4311558A3 (en) Antibodies that bind il-23
JP2015514423A5 (en)
GB201003701D0 (en) System for the expression of a protein
EA201491471A1 (en) COMPOSITION CONTAINING ANTIBODY AGAINST IL-17
CY1119351T1 (en) ADP-RIBOZYL CYCLOTES 2
PE20180797A1 (en) IL22 IMMUNOCONJUGATES
WO2014155278A3 (en) Methods of treating autoimmune diseases using il-17 antagonists
UA113080C2 (en) A SPECIFIC ANTIBODY THAT SPECIFICALLY Binds to IL17 AND BAFF
CL2014001263A1 (en) Bispecific binding molecule for bcma and cd3; nucleic acid sequence that encodes it; vector; cell; pharmaceutical composition comprising the binding molecule; use to treat diseases related to plasma cell disorders, b cell disorders correlated with bcma expression and autoimmune diseases.
TN2014000413A1 (en) Anti-baff-anti-il-17 bispecific antibodies
TH1401006266A (en) ANTI-BAFF-ANTI-IL-17 Bspecific Antibody
EA202090901A1 (en) MULTI-SPECIFIC ANTIBODY
TN2013000144A1 (en) Methods of treating rheumatoid arthuritis using il-17 antagonists